Merck, Ridgeback Highlight Interim Molnupiravir Data In Non-Hospitalized COVID-19 Patients

  • Merck & Co Inc MRK and its collaborating partner Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir in non-hospitalized COVID-19 patients.
  • The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases.
  • In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in 2H of 2021.
  • As reported earlier, the percentage of hospitalized patients or died in Part 1 of the study was lower in the combined molnupiravir-treated groups versus the placebo arm.
  • The most significant overall magnitude of the antiviral effect was observed in the 800 mg dose compared with the 200 mg and 400 mg doses.
  • Price Action: MRK shares traded lower by 0.14% at $77.88 premarket on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCovid-19
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!